Pharmacokinetic profile of defibrotide in patients with renal impairment. - Wikidata - wikimedia - TriplyDB

Pharmacokinetic profile of defibrotide in patients with renal impairment.

Pharmacokinetic profile of defibrotide in patients with renal impairment.

http://www.wikidata.org/entity/Q37194132

about

Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure

P2860

Q38616218-D8E299BE-7000-44EB-B961-DEF173DE0551 Q45067466-466DAE69-27C4-4792-9BA2-2830268BEBEC Q50189731-FCD65797-50C8-4428-9130-2A3EA2A7EE6A Q57301971-2DE8BC24-78B5-4CBE-8C1F-CCF8BF676434

P2860

Pharmacokinetic profile of defibrotide in patients with renal impairment.

http://www.wikidata.org/entity/Q37194132

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmacokinetic profile of defibrotide in patients with renal impairment.

@en

Pharmacokinetic profile of defibrotide in patients with renal impairment.

@nl

type

label

Pharmacokinetic profile of defibrotide in patients with renal impairment.

@en

Pharmacokinetic profile of defibrotide in patients with renal impairment.

@nl

prefLabel

Pharmacokinetic profile of defibrotide in patients with renal impairment.

@en

Pharmacokinetic profile of defibrotide in patients with renal impairment.

@nl

P1433

Q37194132-4D709A8C-A5AA-48B3-8D2C-58A362AF40E7

P1476

Q37194132-60EC2AB8-1E29-435C-8B11-E65E5DEFB0DE

P2093

Q37194132-5D9800BF-642C-4D4B-BEB9-5703D0EB7D92

Q37194132-8833B548-5B78-4886-B887-8A9E9B72D351

Q37194132-A074A713-8BEC-434C-AD67-BE63F4E1798C

Q37194132-F0F8D588-AD82-4374-AE65-8936AF3B64FE

Q37194132-FA983073-146A-4199-8B2A-312252DB2D6E

Q37194132-FDC9B952-7D8E-45B7-B514-C8DC9C027220

P2860

Q37194132-1B023AD6-627A-470A-9010-B721507E7AF6

Q37194132-1FF33BCA-9341-4B0C-B349-8C82EDCB48AF

Q37194132-34EFFF1D-8B58-43C8-B35E-66923EF60010

Q37194132-3D5FCC1B-8FBD-4B42-8E81-1E7D34F15E49

Q37194132-4128C83C-7AAE-4121-95D8-59F339ACD9AC

Q37194132-4E0CB85B-4678-4F9C-BE78-8B5D718475B8

Q37194132-4E0F7686-0717-44CF-BC4B-EB7588E0F8D4

Q37194132-4E96000F-B75C-4A5C-8F21-CEB00C02627D

Q37194132-50C5F109-EA99-413C-A53E-56AB93AF6552

Q37194132-53E46A5D-7875-4ED9-BCA1-4483F175A011

P304

Q37194132-BC686FF2-B2B0-402D-A4BF-EFD2EC71FA64

P31

Q37194132-B5A2ACCC-9F92-4B2A-896B-DA75B3F9DA1A

P356

Q37194132-9FA9D34D-D8B3-4F7B-8299-12AA27760F4F

P407

Q37194132-E9E1DE3A-FC12-4E32-A1CA-4DD968DA1B40

P478

Q37194132-1DFAA579-A45C-4630-B99F-0B3D10DDFEC3

P577

Q37194132-91EE256F-D4EB-4D55-A1BC-5CFC9D3037FC

P698

Q37194132-4FC71026-CFA4-414F-8AAB-ED96BF3B1B55

P932

Q37194132-30978A6E-0E0A-4278-88FF-D4BB71EDFEFA

P356

P1433

Drug Design, Development and Therapy

P1476

Pharmacokinetic profile of defibrotide in patients with renal impairment.

@en

P2093

Elena Tudone

http://www.w3.org/2001/XMLSchema#string

Jean-Francois Marier

http://www.w3.org/2001/XMLSchema#string

Katie Zomorodi

http://www.w3.org/2001/XMLSchema#string

Mark Eller

http://www.w3.org/2001/XMLSchema#string

Paola Tocchetti

http://www.w3.org/2001/XMLSchema#string

Thomas C Marbury

http://www.w3.org/2001/XMLSchema#string

P2860

Dosing of antibiotics in critically ill patients: are we left to wander in the dark?

Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

Effects of defibrotide in acute renal failure due to thrombotic microangiopathy.

The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade.

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.

Hepatic veno-occlusive disease following hematopoietic stem cell transplantation.

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.

Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation.

Veno-occlusive disease of the liver in the absence of elevation in bilirubin in pediatric patients after hematopoietic stem cell transplantation.

P304

2631-2641

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S112181

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27574402

http://www.w3.org/2001/XMLSchema#string

P932

4993270

http://www.w3.org/2001/XMLSchema#string